- On March 8, the FDA approved the use of Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with heart disease with obesity or overweight.
- In 2021, the FDA approved the semaglutide-containing medication for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
- Semaglutide was originally approved by the FDA in 2017 to treat type 2 diabetes in adults.
On March 8, the FDA
The indication recommends using semaglutide in addition to a reduced-calorie diet and increased physical activity.
In 2021, the FDA
Semaglutide medications belong to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists that were originally developed to treat type 2 diabetes. GLP-1 drugs have since exploded in popularity as a weight loss treatment.
In recent years, researchers have examined how semaglutide affects cardiovascular health. A
A
Dr. Cheng-Han Chen, a board certified interventional cardiologist and medical director of the Structural Heart Program at MemorialCare Saddleback Medical Center in Laguna Hills, CA, explained to Medical News Today how a diabetes and weight loss drug could help with cardiovascular health.
Dr. Chen said that…
Read the full article here